Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > comgrats

<< Previous

Bullboard Posts

Next >>

Comment by MrMugsyon Nov 23, 2023 8:35pm

279 Views

Post# 35750879

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:comgrats

Not sure why you think chronic has to go through preclinical but you stay on that path. That's a conservative way to look at it.

I'm more interested in the pipeline and I have been for a very long time - but - I know it requires money.

Regardless - all eyes on P2 acute for now ... with DILIsym work underway for chronic.

New molecule to be anounced in the New Year ... or will it ?

<< Previous

Bullboard Posts

Next >>

Advancing flagship Ishkõday Gold Project in Ontario